// App-Quantinova.ai

9550 : Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma.

Researchers

Presenter

  • Michael A. Postow

Principal Investigators

  • Susan Jane Knox

  • Debra Goldman

  • Katherine Panageas

  • Darragh Halpenny

  • Danielle McCabe

  • Mary J. Macri

  • Paul Schwarzenberger

  • Toni Ricciardi

  • Aileen Ryan

  • Ralph Rudolph Venhaus

  • Christopher Andrew Barker

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Stanford School of Medicine, Stanford, CA

  • Ludwig Cancer Research, New York, NY

  • Ludwig Institute for Cancer Research, Ltd., New York, NY

  • Ludwig Institute for Cancer Research, Ltd., New York, NY

Locations

  • United States

Companies

  • Ludwig Institute for

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • I

Study Id's

  • NCT02659540

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved